摘要
背景:β地中海贫血的表型严重程度受β-珠蛋白突变、α-地中海贫血的共遗传和与胎儿血红蛋白产生相关基因的多态性三种遗传修饰因子的高度调控。本研究旨在探讨HBF相关基因主要存在于HBB簇、BCL11A(B细胞CLL/淋巴瘤11A)和HBS1L-MYB(HBS 1样翻译型GTPase-MYB原癌基因、转录因子)对临床严重程度的影响。方法:对149例患者进行调查。采用多重PCR、Sanger测序和多重连接依赖探针扩增技术对HBA和HBB突变进行分析。此外,采用质谱和PCR-限制性片段长度多态性(PCRRFLP)对35种HBF多态性进行了基因分型。用SPSSVersion 22进行基因型-表型关联分析。结果:在研究人群中发现了21个HBB突变.HBB突变患者由于其他次级修饰物的存在,其表型严重程度不同。α-地中海贫血的共遗传(n=12)减轻了β-地中海贫血的疾病严重程度.3种多态性(HBS1LMYB,rs4895441[P=0.008,OR=0.38(0.18,0.78)],rS 9376092[P=0.030,OR=0.36(0.14,0.90)];嗅觉受体[OR51B2]rs6578605[P=0.018,OR=0.52(0.31,0.89)]与表型严重程度有关。对HBF单核苷酸多态性与HBF水平关系的二次分析表明,HBS1L-MYB中有三个表面意义显著的SNPs:rs 6934903、rs 9376095和rs 9494149。结论:本研究揭示了3种HBF多态性在改善β-地中海贫血患者病情严重程度中的重要作用,可作为临床管理的预测指标。
关键词: β-地中海贫血,HBF修饰物,疾病严重程度,基因型-表型关联,多态性,突变。
Current Molecular Medicine
Title:Genetic Modifiers of Fetal Haemoglobin (HbF) and Phenotypic Severity in β-Thalassemia Patients
Volume: 18 Issue: 5
关键词: β-地中海贫血,HBF修饰物,疾病严重程度,基因型-表型关联,多态性,突变。
摘要: Background: The phenotypic severity of β-thalassemia is highly modulated by three genetic modifiers: β-globin (HBB) mutations, co-inheritance of α-thalassemia and polymorphisms in the genes associated with fetal haemoglobin (HbF) production. This study was aimed to evaluate the effect of HbF related polymorphisms mainly in the HBB cluster, BCL11A (B-cell CLL/lymphoma 11A) and HBS1L-MYB (HBS1-like translational GTPase-MYB protooncogene, transcription factor) with regards to clinical severity.
Methods: A total of 149 patients were included in the study. HBA and HBB mutations were characterised using multiplex PCR, Sanger sequencing and multiplex ligationdependent probe amplification. In addition, 35 HbF polymorphisms were genotyped using mass spectrometry and PCR-restriction fragment length polymorphism (PCRRFLP). The genotype-phenotype association was analysed using SPSS version 22.
Results: Twenty-one HBB mutations were identified in the study population. Patients with HBB mutations had heterogeneous phenotypic severity due to the presence of other secondary modifiers. Co-inheritance of α-thalassemia (n = 12) alleviated disease severity of β-thalassemia. In addition, three polymorphisms (HBS1LMYB, rs4895441 [P = 0.008, odds ratio (OR) = 0.38 (0.18, 0.78)], rs9376092 [P = 0.030, OR = 0.36 (0.14, 0.90)]; and olfactory receptor [OR51B2] rs6578605 [P = 0.018, OR = 0.52 (0.31, 0.89)]) were associated with phenotypic severity. Secondary analysis of the association between single-nucleotide polymorphisms with HbF levels revealed three nominally significant SNPs: rs6934903, rs9376095 and rs9494149 in HBS1L-MYB.
Conclusion: This study revealed 3 types of HbF polymorphisms that play an important role in ameliorating disease severity of β-thalassemia patients which may be useful as a predictive marker in clinical management.
Export Options
About this article
Cite this article as:
Genetic Modifiers of Fetal Haemoglobin (HbF) and Phenotypic Severity in β-Thalassemia Patients, Current Molecular Medicine 2018; 18 (5) . https://dx.doi.org/10.2174/1566524018666181004121604
DOI https://dx.doi.org/10.2174/1566524018666181004121604 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Rho-Signaling Pathways in Chronic Myelogenous Leukemia
Cardiovascular & Hematological Disorders-Drug Targets Surface Plasmon Resonance Imaging Sensor for Cathepsin Determination Based on Immobilized Cystatin
Protein & Peptide Letters Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems
Current Pharmaceutical Biotechnology New Strategies in the Discovery of Novel Non-Camptothecin Topoisomerase I Inhibitors
Current Medicinal Chemistry The Radionuclide Molecular Imaging and Therapy of Neuroendocrine Tumors
Current Cancer Drug Targets A Case Series of Malign Hyperechoic Breast Lesions
Current Medical Imaging Synthesis, In Vitro Anticancer, Anti-Inflammatory and DNA Binding Activity of Thiazolidinedione Derivatives
Anti-Cancer Agents in Medicinal Chemistry Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML)
Current Drug Targets Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis
Current Drug Targets Regulation of the Immune Response by Natural IgM: Lessons from Warm Autoimmune Hemolytic Anemia
Current Pharmaceutical Design Is Technical-Grade Chlordane an Obesogen?
Current Medicinal Chemistry The Medical Use of Wheatgrass: Review of the Gap Between Basic and Clinical Applications
Mini-Reviews in Medicinal Chemistry Targeting Cancer Stem Cells as a Therapeutic Approach in Liver Cancer
Current Gene Therapy In Vitro and In Vivo Sirolimus for Modulation of Allogeneic Hematopoietic Stem Cell Transplantation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Therapeutic Vaccines for Cervical Cancer: Dendritic Cell-Based Immunotherapy
Current Pharmaceutical Design Vincristine-Induced Seizure Potentiated by Itraconazole Following RCHOP Chemotherapy for Diffuse Large B-Cell Lymphoma
Current Drug Safety The Inhibitor of Growth (ING) Gene Family: Potential Role in Cancer Therapy
Current Cancer Drug Targets Differential Role of Apoptosis and Autophagy Associated with Anticancer Effect of Lupulone (Hop β-Acid) Derivatives on Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Design, Synthesis and in vitro Cytotoxicity Evaluation of New 3',4'-bis (3,4,5-trisubstituted)-4'H-spiro[indene-2,5'-isoxazol]-1(3H)-one Derivatives as Promising Anticancer Agents
Letters in Drug Design & Discovery NMN/NaMN Adenylyltransferase (NMNAT) and NAD Kinase (NADK) Inhibitors: Chemistry and Potential Therapeutic Applications
Current Medicinal Chemistry